# TQB2930

Source: https://onco.cc/drugs/tqb2930/  
OnCo record `tqb2930` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TQB2930 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER2 and EGFR.

## Summary

TQB2930 is a bispecific antibody developed by Chia Tai Tianqing Pharmaceutical and Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical. Its targets are HER2 and EGFR (the sponsor names HER2). The sponsor states: TQB2930 is a HER2 bispecific antibody given by intravenous infusion, being studied as monotherapy or combination therapy in HER2-positive recurrent/metastatic breast cancer. ClinicalTrials.gov describes the intervention as: TQB2930 for injection is a HER2 bispecific antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in HR-positive / HER2-negative breast cancer. The largest, NCT07512583, plans to enrol 178 participants with primary completion expected 2028-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: TQB2930 is a HER2 bispecific antibody given by intravenous infusion, being studied as monotherapy or combination therapy in HER2-positive recurrent/metastatic breast cancer.

## Sources

- ClinicalTrials.gov: trials of TQB2930: https://clinicaltrials.gov/search?intr=TQB2930

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [HER2](https://onco.cc/targets/her2/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06202261/), [Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct07512583/), [TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct07047365/)

---
JSON: https://onco.cc/api/v1/entities/tqb2930.json